Gapping up
In reaction to strong earnings/guidance:
- PLUS +7.1%, PANW +7.1%, RAMP +6.9%, ELF +6.7%, A +6.2%, SPLK +6.1%, CRMT +4.9%, DE +3%, DECK +2.5%, NVDA +1.7%, PDD +1.6%
Other news:
- TLSA +13.4% (intends to demerge its StemPrintER genomics-based personalized medicine business as a separate listed company )
- AQST +12.8% (announces advancement of monetization strategy for APL-130277)
- OSUR +7.4% (OMNIgene ORAL saliva collection device included in FDA Administration Emergency Use Authorization granted to P23 Labs)
- XENE +3.1% (provides clinical update; has received recent FDA feedback on XEN496 program, co believes it can initiate a Phase 3 trial later this year)
- CDXC +3% (files for 1,225,490 share common stock offering by selling shareholders)
- BBBY +1.9% (announces plans to re-open stores and expand store fulfillment services)
Analyst comments:
- CVTI +2% (upgraded to Overweight from Equal-Weight at Stephens)
- CCI +1.3% (upgraded to Outperform from Perform at Oppenheimer)